Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 26 04:00PM ET
1.81
Dollar change
+0.02
Percentage change
1.12
%
Index- P/E- EPS (ttm)-5.20 Insider Own7.89% Shs Outstand2.21M Perf Week-7.65%
Market Cap4.13M Forward P/E- EPS next Y-3.69 Insider Trans0.00% Shs Float2.10M Perf Month-77.93%
Income-3.59M PEG- EPS next Q-1.19 Inst Own11.02% Short Float1.16% Perf Quarter-56.28%
Sales12.04M P/S0.34 EPS this Y-115.76% Inst Trans- Short Ratio0.10 Perf Half Y-47.38%
Book/sh-0.37 P/B- EPS next Y22.33% ROA-24.26% Short Interest0.02M Perf Year-88.54%
Cash/sh3.75 P/C0.48 EPS next 5Y- ROE- 52W Range1.59 - 17.59 Perf YTD-48.32%
Dividend Est.- P/FCF1.12 EPS past 5Y61.51% ROI- 52W High-89.71% Beta1.26
Dividend TTM- Quick Ratio0.89 Sales past 5Y-40.00% Gross Margin99.88% 52W Low13.84% ATR (14)0.78
Dividend Ex-Date- Current Ratio0.89 EPS Y/Y TTM81.52% Oper. Margin-57.27% RSI (14)33.97 Volatility9.96% 24.87%
Employees17 Debt/Eq- Sales Y/Y TTM-100.00% Profit Margin-29.79% Recom1.67 Target Price37.50
Option/ShortNo / Yes LT Debt/Eq- EPS Q/Q103.48% Payout- Rel Volume0.88 Prev Close1.79
Sales Surprise103.00% EPS Surprise112.50% Sales Q/Q- EarningsMar 05 AMC Avg Volume234.08K Price1.81
SMA20-49.90% SMA50-63.18% SMA200-58.81% Trades Volume204,838 Change1.12%
Date Action Analyst Rating Change Price Target Change
Apr-16-21Upgrade BTIG Research Neutral → Buy $14
Feb-10-21Initiated Maxim Group Buy $24
Dec-23-19Reiterated H.C. Wainwright Buy $15 → $18
Mar-01-19Reiterated Needham Buy $7
Jun-13-17Reiterated Stifel Buy $14 → $6
Dec-21-16Initiated Jefferies Buy $10
Feb-01-16Resumed Oppenheimer Outperform
Jul-29-15Initiated ROTH Capital Buy $18
Mar-02-15Reiterated Stifel Buy $16 → $20
Mar-02-15Reiterated Oppenheimer Outperform $22 → $26
Apr-10-24 06:30AM
Apr-08-24 09:10AM
Apr-03-24 08:00AM
Mar-07-24 10:03AM
Mar-05-24 04:29PM
04:02PM Loading…
04:02PM
Feb-28-24 04:02PM
Dec-20-23 08:00AM
Nov-21-23 07:55AM
07:32AM
Nov-20-23 08:00AM
Nov-13-23 09:29AM
Nov-12-23 08:47AM
Nov-10-23 07:45AM
Nov-09-23 04:58PM
04:02PM Loading…
04:02PM
Oct-31-23 04:02PM
Sep-18-23 08:00AM
Sep-05-23 04:02PM
Aug-25-23 07:20AM
Aug-15-23 08:43AM
Aug-14-23 07:00PM
04:02PM
Aug-02-23 04:05PM
Jul-11-23 08:00AM
Jun-20-23 08:00AM
Jun-16-23 08:00AM
Jun-15-23 08:00AM
Jun-02-23 08:00AM
May-30-23 08:00AM
11:24AM Loading…
May-11-23 11:24AM
May-10-23 04:38PM
04:02PM
May-03-23 04:02PM
Apr-25-23 07:41AM
Apr-06-23 08:30AM
Mar-14-23 12:00PM
Mar-10-23 02:26AM
Mar-09-23 05:49AM
Mar-08-23 04:02PM
Feb-28-23 04:02PM
Jan-20-23 06:55AM
Jan-10-23 08:30AM
Dec-27-22 08:00AM
Dec-14-22 11:29AM
08:00AM
Nov-21-22 08:00AM
Nov-14-22 04:02PM
Oct-31-22 08:00AM
Oct-06-22 08:30AM
08:00AM
Sep-14-22 08:00AM
Sep-07-22 08:00AM
Sep-06-22 08:00AM
Aug-29-22 08:00PM
11:45AM
08:00AM
Aug-10-22 04:02PM
08:00AM
Aug-08-22 08:00AM
Jul-27-22 08:05AM
Jul-26-22 08:05AM
Jun-02-22 08:05AM
May-16-22 08:05AM
May-11-22 04:02PM
May-04-22 08:05AM
Apr-19-22 08:05AM
Apr-08-22 05:02PM
Mar-23-22 08:05AM
Mar-15-22 04:02PM
Mar-11-22 08:05AM
Mar-10-22 08:05AM
Mar-04-22 08:05AM
Feb-02-22 08:05AM
Jan-05-22 08:05AM
Dec-27-21 08:00AM
Nov-29-21 08:05AM
Nov-11-21 08:05AM
Nov-03-21 04:02PM
Oct-27-21 08:05AM
Oct-13-21 08:00AM
Oct-11-21 01:27PM
08:00AM
Sep-13-21 08:05AM
Sep-07-21 08:05AM
07:29AM
Sep-02-21 08:05AM
Aug-11-21 04:02PM
Aug-09-21 08:05AM
Aug-03-21 08:05AM
Jul-28-21 08:05AM
Jul-21-21 10:30PM
05:27PM
Jul-20-21 08:05AM
Jun-30-21 08:05AM
Jun-29-21 08:05AM
Jun-28-21 01:04PM
Jun-18-21 10:08AM
Jun-04-21 09:01AM
Jun-01-21 08:05AM
TRACON Pharmaceuticals, Inc. engages in the development and commercialization of targeted therapies for cancer, and ophthalmic and fibrotic diseases. Its products include TRC105, an anti-endoglin antibody for the treatment of solid tumor types, TRC205 created for the treatment of fibrotic diseases, and TRC102, a small molecule that is in clinical development made for lung cancer and glioblastoma. The company was founded in October 2004 and is headquartered in San Diego, CA.